Certest Showcases Range of Rapid Tests and Real Time PCR Detection Kits at MEDICA 2021
|
By LabMedica International staff writers Posted on 15 Nov 2021 |

CerTest Biotec (Zaragoza, Spain) showcased its range of rapid tests and real time PCR detection kits at the MEDICA 2021 trade fair held in Düsseldorf, Germany from 15-18th November. MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals.
CerTest highlighted different products for infectious diseases, tumor and inflammation markers detection. The company also presented its range of enzymes for molecular biology and qPCR. CerTest highlighted its range of monoclonal antibodies with high sensitivity and specificity by using highly stable and pure immunogens and an in-house improved screening; liquid recombinant proteins with high purity and stability, through a process of cloning, expression, multi-step purification and buffer optimization; native antigens -inactivated- comprising a wide variety of bacteria and viruses; and molecular biology enzymes with high specific activity and high stability, with and w/o glycerol that are suitable for qPCR and RT-qPCR.
CerTest also presents its rapid test diagnostic products for detecting the presence of antigens with the immunochromatographic lateral flow technique. These products included rapid diagnostic tests for gastrointestinal, respiratory infectious diseases, and the detection of inflammatory or tumor markers in the GI tract. The company demonstrated why its rapid tests are easy to use, along with its robust and stable diagnostic devices that are designed to provide the best performance in the simplest way and at the lowest associated operational costs. Also on display was CerTest’s Turbilatex product line including turbidimetric assays based on the agglutination reaction between antibody-coated latex particles and the antigen in solution, as well as reagents that permit a high-sensitivity detection method to be obtained. The intended use for Turbilatex products is to detect and quantify the antigen present in human stool samples.
Additionally, CerTest showcased its VIASURE Real Time PCR Detection Kits that are designed for the diagnosis of infectious diseases caused by different pathogens in human samples. This product range is based on 5’ nuclease chemistry. This technology utilizes two primers and a hydrolysis probe and exploits the exonuclease activity of Taq DNA polymerase. During the amplification, the increase in the fluorescent signal is proportional to the quantity of target sequence present in the sample and could be measured on a wide range of Real Time PCR platforms. VIASURE Real Time PCR Detection Kit contains in each well all the necessary components for Real Time PCR assay in a stabilized format, which allows the shipment at room temperature.
Related Links:
CerTest Biotec
Latest Medica 2021 News
- MEDICA 2021 + COMPAMED 2021 Far Exceed Expectations and Achieve Extremely Successful Results
- POC System that Requires Single DNA Molecule for Rapid Detection of Multidrug-Resistant Pathogens Unveiled at MEDICA 2021
- Icomes Lab Demonstrates World's Smallest and Lightest Electronic Pipette for PCR Testing at MEDICA 2021
- Bosch Exhibits Vivalytic All-in-One Analyzer for PCR Rapid Tests at MEDICA 2021
- Co-Diagnostics Introduces Its Revolutionary Coprimer Technology at MEDICA 2021
- MGI Tech Showcases World-First High-Throughput Automated Sample Transfer Processing System at MEDICA 2021
- Edan Debuts Next-Gen Blood Gas & Chemistry Analyzer and Patient Monitor at MEDICA 2021
- EKF Diagnostics Showcases STAT-Site WB β-ketone and Glucose Handheld Analyzer Live & in Person at MEDICA 2021
- Boditech Launches New Automated Immunoassay Analyzer with Blood Collection Tube at MEDICA 2021
- Molgen Presents Diagnostics Chemistry, Flows and Systems at MEDICA 2021
- Randox Showcases Extensive Range of Revolutionary Diagnostic Analyzers at MEDICA 2021
- Molbio Exhibits Its Novel POC Molecular Platform and Truenat Range of Tests at MEDICA 2021
- Greiner Bio-One Exhibits Its New Generation of Sapphire Pipette Tips at MEDICA 2021
- LumiraDx Presents Its Innovative, Next Generation Point of Care Diagnostics Platform at MEDICA 2021
- Medix Biochemica Celebrates Launch of New Molecular Diagnostic Reagents Division at MEDICA 2021
- Fujirebio Highlights Its Innovative IVD Testing Solutions for Today and Tomorrow at MEDICA 2021
Channels
Clinical Chemistry
view channel
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read more
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read moreMolecular Diagnostics
view channel
RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
Many patients with advanced solid tumors exhaust broad DNA panel testing yet still lack biomarkers that match guideline-recommended therapies, limiting access to targeted options. Expanding molecular profiling... Read more
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more








